Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Moderate Buy” by Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.50.

Several analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Oppenheimer restated an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Zacks Research lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Barclays assumed coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $7.34 on Friday. The firm’s 50-day moving average is $7.88 and its two-hundred day moving average is $6.86. The company has a market capitalization of $1.22 billion, a PE ratio of -73.39 and a beta of 0.57. Xeris Biopharma has a 12-month low of $3.14 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. On average, analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the transaction, the director directly owned 142,500 shares in the company, valued at approximately $1,010,325. This represents a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.01, for a total value of $116,835.67. Following the completion of the sale, the insider owned 1,320,176 shares of the company’s stock, valued at $9,254,433.76. This trade represents a 1.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 206,976 shares of company stock valued at $1,497,495. 6.47% of the stock is owned by company insiders.

Institutional Trading of Xeris Biopharma

Institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC purchased a new position in shares of Xeris Biopharma in the 3rd quarter worth $35,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Xeris Biopharma in the 3rd quarter valued at about $68,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Xeris Biopharma during the 3rd quarter worth about $85,000. Finally, FORA Capital LLC acquired a new stake in Xeris Biopharma during the 1st quarter worth approximately $60,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.